STOCK TITAN

AgomAb Therapeutics: Redmile reports 3.5% stake

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

For AgomAb Therapeutics NV (AGMB), Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report beneficial ownership of 1,740,230 common shares, or 3.5%, as of September 30, 2026. The reports concern the same position, not three separate holdings: the American Depositary Shares are directly held by Redmile Biopharma Investments III, and each ADS represents one common share.

Redmile and Green may be deemed beneficial owners through Redmile’s role as investment manager and Green’s role as its principal; each disclaims beneficial ownership except to the extent of any pecuniary interest. The 3.5% calculation uses 49,247,975 common shares outstanding as of March 31, 2026.

Reported beneficial ownership 1,740,230 common shares each Each of the three reporting persons reports the same position as of September 30, 2026.
Ownership percentage 3.5% Reported by each reporting person; based on 49,247,975 common shares outstanding as of March 31, 2026.
Common shares outstanding 49,247,975 shares As of March 31, 2026; the basis for the reported ownership percentage.
ADS ratio 1 ADS represents 1 common share Each American Depositary Share represents one common share.
beneficial ownership regulatory
"beneficial ownership of Common Shares"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
American Depositary Shares financial
"1,740,230 American Depositary Shares"
American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.
shared voting power regulatory
"Shared power to vote or to direct the vote"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power regulatory
"Shared power to dispose or to direct the disposition"
investment manager financial
"in its capacity as the investment manager"
pecuniary interest financial
"except to the extent of its or his pecuniary interest"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many AGMB shares do the reporting persons beneficially own?

Redmile Group, LLC, Jeremy C. Green, and Redmile Biopharma Investments III, L.P. each report 1,740,230 common shares, equal to 3.5% of the class, as of September 30, 2026. Redmile Biopharma Investments III directly holds the ADSs, and each ADS represents one common share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





00860C102

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: The information in Item 4 relating to the Issuer's common shares, no nominal value per share ("Common Shares"), that are or may be deemed beneficially owned by Redmile Group, LLC ("Redmile") is incorporated herein by reference.


SCHEDULE 13G




Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Jeremy C. Green is incorporated herein by reference.


SCHEDULE 13G




Comment for Type of Reporting Person: The information in Item 4 relating to the Common Shares that are or may be deemed beneficially owned by Redmile Biopharma Investments III, L.P. ("RBI III") is incorporated herein by reference.


SCHEDULE 13G



Redmile Group, LLC
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member
Date:11/16/2026
Jeremy C. Green
Signature:/s/ Jeremy C. Green
Name/Title:Jeremy C. Green
Date:11/16/2026
Redmile Biopharma Investments III, L.P.
Signature:/s/ Jeremy C. Green
Name/Title:Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P.
Date:11/16/2026

Keep reading